THIRD AMENDMENT TO MERGER AGREEMENT
EXHIBIT 2(a.3)
EXECUTION COPY
THIRD AMENDMENT TO MERGER AGREEMENT
THIS THIRD AMENDMENT TO MERGER AGREEMENT (this “Third Amendment”) is made on the 21st day of
April, 2009, by and among DUSA Pharmaceuticals, Inc., a company incorporated in the State of New
Jersey, with principal offices at 00 Xxxxx Xxxxx, Xxxxxxxxxx, Xxxxxxxxxxxxx (“DUSA”), Xxxxx
Xxxxxxx, residing at 0000 Xxxxxxxxx Xxxxx, Xxxx Xxxxx, XX 00000 and Xxxxxxx Xxxxxxxxx, residing at
0000 Xxxxx Xxx Xxxxx, Xxx Xxxxxxx, XX 00000 (collectively hereinafter referred to as the
“Shareholder Representatives”) and those certain shareholders of the former Sirius Laboratories,
Inc., a company incorporated in the State of Illinois (“Sirius Illinois”) set forth on the
signature page hereto (each a “Principal Shareholder” and collectively the “Principal
Shareholders”). DUSA, the Shareholder Representatives and the Principal Shareholders are at times
referred to each as a “Party” and collectively as the “Parties.” All capitalized terms used, but
not specifically defined herein, shall have the meaning provided for such terms in the Merger
Agreement (as defined below).
RECITALS
WHEREAS, DUSA, Sirius Illinois and the Principal Shareholders previously entered into that
certain Merger Agreement, dated December 30, 2005, as amended, (the “Merger Agreement”) whereby
such parties subsequently effected a merger of Sirius Illinois with and into a wholly-owned
subsidiary of DUSA; and
WHEREAS, the shareholders of Sirius Illinois appointed the Shareholder Representatives; and
WHEREAS, the Parties wish to amend certain terms of the Merger Agreement in accordance with
Section 15.8 of the Merger Agreement, as provided for herein.
NOW, THEREFORE, the Parties, in furtherance of the foregoing and for good and valuable
consideration, the receipt and adequacy of which are hereby acknowledged, intending to be legally
bound, agree as follows:
1. As of the date of this Third Amendment, the definition of the Milestone Terminate Date in
Section 1.76 of the Merger Agreement shall be amended to state “Milestone Termination Date means
December 31, 2011.”
2. As of the date of this Third Amendment, the definition of Net Sales in Section 1.79 of the
Merger Agreement shall be amended by adding to the end thereof: “(iii) payments received by DUSA
pursuant to the divestiture of all rights, title and interest to a Product, including the
Intellectual Property Rights associated with any such Product.”
3. As of the date of this Third Amendment, a new Section 1.115a shall be added to the Merger
Agreement immediately following Section 1.115 thereof and shall read as follows:
1.115a “Third Amendment” means the Third Amendment to Merger Agreement
between DUSA, the Shareholder Representatives and the Principal
Shareholders, dated April 21, 2009.
4. Section 10.4(b) shall be deleted.
5. As of the date of this Third Amendment, Section 15.10 of the Merger Agreement shall be
deleted in its entirety and the following shall be inserted in its place and stead:
15.10 Assignments, Successors, and No Third-Party Rights. No party
may assign any of its rights or delegate its obligations under this
Agreement without the prior consent of the other parties, except that DUSA
may assign its rights or delegate its obligations hereunder to its
Affiliates so long as DUSA remains ultimately liable for all of DUSA’s
obligations hereunder. Notwithstanding the foregoing, DUSA shall have the
sole right to manage all business matters related to the Products and New
Products, including, but not limited to, any and all activities relating to
licensing, marketing, promoting, detailing, distributing, manufacturing,
selling, transferring or offering the Products or New Products in DUSA’s
sole discretion without the consent of the other Parties; all such decisions
made pursuant to this Section 15.10 shall not be deemed an assignment or a
delegation of obligations under this Section 15.10. Subject to the
preceding sentences, this Agreement will apply to, be binding in all
respects upon, and inure to the benefit of the successors and permitted
assigns of the parties. Nothing expressed or referred to in this Agreement
will be construed to give any Person other than the parties to this
Agreement any legal or equitable right, remedy, or claim under or with
respect to this Agreement or any provision of this Agreement. This
Agreement and all of its provisions and conditions are for the sole and
exclusive benefit of the parties to this Agreement and their successors and
assigns.
6. All other terms and conditions of the Merger Agreement shall remain unchanged and in full
force and effect.
7. This Third Amendment shall not constitute a waiver or modification of any of the Parties’
rights and remedies or of any of the terms, conditions, warranties, representations, or covenants
contained in the Merger Agreement, except as specifically set forth above, and each Party hereby
reserves all of its rights and remedies pursuant to the Merger Agreement and applicable law, and
except as otherwise set forth in that certain Release Agreement, dated as of the date hereof,
between DUSA and its wholly-owned subsidiary, Sirius Laboratories, Inc., the Shareholders
Representatives and the Principal Shareholders.
8. This Third Amendment may be executed in counterparts, each of which, when taken together,
shall be deemed to be one and the same instrument.
[Signature Pages Follow]
-2-
IN WITNESS WHEREOF, the parties have executed and delivered this Third Amendment to Merger
Agreement as of the date first written above.
DUSA Pharmaceuticals, Inc. |
||||
By: | /s/ Xxxxxxx Xxxxxxxxxxx | |||
Name: | Xxxxxxx Xxxxxxxxxxx | |||
Title: | VP Finance & CFO | |||
PRINCIPAL SHAREHOLDERS |
||||
/s/ Xxxxx X. Xxxxxxx | ||||
Xxxxx X. Xxxxxxx | ||||
/s/ Xxxx X. Xxxxxxx | ||||
Xxxx X. Xxxxxxx | ||||
/s/ Xxxxxxx X. Xxxxxxxxx | ||||
Xxxxxxx X. Xxxxxxxxx Ph.D. | ||||
/s/ Xxxxxx Xxxxxxxxx | ||||
Xxxxxx Xxxxxxxxx | ||||
/s/ Xxxx Xxxxxxxxx | ||||
Xxxx Xxxxxxxxx, M.D. | ||||
/s/ Xxxxx Xxxxxxxxx | ||||
Xxxxx Xxxxxxxxx | ||||
/s/ Xxxxxxx Xxxxxx | ||||
Xxxxxxx Xxxxxx | ||||
/s/ Xxxxx X. Xxxxxxx | ||||
Xxxxx X. Xxxxxxx, Xx. | ||||
/s/ Xxxxx X. Xxxxxxx | ||||
Xxxxx X. Xxxxxxx | ||||
-3-
/s/ Xxxxx X. Xxxxxxx | ||||
Xxxxx X. Xxxxxxx | ||||
/s/ Xxxxx X. Xxxxxx | ||||
Xxxxx X. Xxxxxx | ||||
/s/ Xxxxxx Xxxxxx | ||||
Xxxxxx Xxxxxx | ||||
/s/ Xxxxxxxxx Xxxxxxx | ||||
Xxxxxxxxx Xxxxxxx | ||||
/s/ Xxxxx Xxxxxxx | ||||
Xxxxx Xxxxxxx | ||||
/s/ Xxxxx X. Xxxxxxx | ||||
Xxxxx X. Xxxxxxx | ||||
SHAREHOLDER REPRESENTATIVES |
||||
By: | /s/ Xxxxx Xxxxxxx | |||
Name: | Xxxxx Xxxxxxx | |||
By: | /s/ Xxxxxxx Xxxxxxxxx | |||
Name: | Xxxxxxx Xxxxxxxxx | |||
-4-